Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Inclusion Criteria:

1. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2

2. Subjects who are non-smokers for at least 3 months prior to screening

3. Subjects who are willing and able to be confined to the clinical research facility as
required by the protocol

Exclusion Criteria:

1. Subjects with a clinically significant history of allergy to drugs or latex.

2. Subjects with a history of alcohol or drug dependence in the past 12 months.

3. Subjects who have donated a significant amount of blood in the past 2 months

4. Female subjects who are pregnant or breastfeeding

5. Subjects who are not willing to use an adequate form of birth control during the
study and for 30 days after discharge from clinic

6. Subjects who have taken an investigational drug in the past 30 days or 7 half-lives
of the investigational drug, whichever is longer

7. Subjects who had previously received anti-diabetic medication, including metformin,
sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4
inhibitors or sulfonylureas), or SGLT2 inhibitors, in the past 3 months